Brief: Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial
08/04/2025 12:04
April 8 (Reuters) - Cartesian Therapeutics Inc RNAC.O: CARTESIAN THERAPEUTICS’ DESCARTES-08 OBSERVED TO PROVIDE DEEP AND SUSTAINED BENEFITS THROUGH MONTH 12 AFTER A SINGLE COURSE OF THERAPY IN PHASE 2B MYASTHENIA GRAVIS TRIAL CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TRIAL ON TRACK TO DOSE FIRST PATIENT IN 2Q25 CARTESIAN THERAPEUTICS-SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND CONTINUES TO SUPPORT OUTPATIENT ADMINISTRATION Source text: ID:nGNX26N9Dk Further company coverage: RNAC.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview